Analysis finds mixed results for use of thrombolytic therapy for blood clot in lungs

June 17, 2014

In an analysis that included data from 16 trials performed over the last 45 years, among patients with pulmonary embolism, receipt of therapy to dissolve the blood clot (thrombolysis) was associated with lower rates of death, but increased risks of major bleeding and intracranial hemorrhage, according to a study in the June 18 issue of JAMA. The authors note that these findings may not apply to patients with low-risk pulmonary embolism.

Pulmonary embolism (PE; a blockage of the main artery of the lung or one of its branches) is an important cause of illness and death, with more than 100,000 U.S. cases annually and as many as 25 percent of experiencing sudden death. Pulmonary embolism is also associated with an increased risk of death for up to 3 months after the initial event. Thrombolytic therapy may be beneficial in the treatment of some patients with PE, but to date, no analysis has had adequate statistical power to determine whether this therapy is associated with improved survival, compared with conventional anticoagulation, according to background information in the article.

Saurav Chatterjee, M.D., of St. Luke's-Roosevelt Hospital Center of the Mount Sinai Health System, New York, and colleagues performed a meta-analysis of 16 randomized clinical trials (n = 2,115 patients) of thrombolytic therapy for PE. Two hundred ten patients (9.9 percent) had low-risk PE, 71 percent had intermediate-risk PE, 1.5 percent had high-risk PE; risk could not be classified in 18 percent.

The researchers found that thrombolytic therapy for PE was associated with a 47 percent lower odds of death; there was 2.2 percent mortality in the thrombolytic therapy group and 3.9 percent mortality in the anticoagulant group at an average duration of follow-up of 82 days. Thrombolytic therapy was associated with a 2.7 times greater risk of compared with anticoagulant therapy; there was a 9.2 percent rate of major bleeding in the thrombolytic therapy group and a 3.4 percent rate in the anticoagulation group. Major bleeding was not significantly increased in patients 65 years and younger.

Thrombolysis was associated with a greater intracranial hemorrhage rate (1.5 percent vs 0.2 percent) but also lower risk of recurrent PE (1.2 percent vs 3.0 percent).

In intermediate-risk trials, thrombolysis was associated with lower mortality and more major bleeding events.

"Risk stratification models for bleeding in all patients, but especially the elderly, are warranted to identify the individuals at the highest risk of hemorrhagic complications with thrombolytic therapy. Future research should also be directed toward concomitant [accompanying] use of other medications, especially the 'novel oral anticoagulants' in conjunction with thrombolytics in patients with hemodynamically stable PE," the authors write.

"The meta-analysis by Chatterjee et al raises new questions," writes Joshua A. Beckman, M.D., of Brigham and Women's Hospital, Boston, in an accompanying editorial.

"For example, should thrombolytic therapy in intermediate-risk patients older than 65 years be avoided? While the risk of bleeding is increased in older patients, the point estimate for mortality is similar to that in younger patients. Risk stratification for bleeding may favor use of thrombolysis in patients older than 65 years. Second, would the net clinical benefit be better with consistent use of catheter-based thrombolysis using lower doses of fibrinolytic agents for significant pulmonary artery thrombus [blood clot] reduction? Additional clinical trials are needed to guide optimal use of thrombolytic in patients with PE."

Explore further: Benefits / risks for fibrinolytic therapy in intermediate-risk PE

More information: DOI: 10.1001/jama.2014.5990 and DOI: 10.1001/jama.2014.5993

Related Stories

Benefits / risks for fibrinolytic therapy in intermediate-risk PE

April 11, 2014
(HealthDay)—A single intravenous bolus of tenecteplase reduces early death and hemodynamic decompensation in normotensive patients with intermediate-risk pulmonary embolism, but increases the risk of major hemorrhage and ...

For embolism patients, clot-busting drug is worth risk

February 21, 2013
When doctors encounter a patient with a massive pulmonary embolism, they face a difficult choice: Is it wise to administer a drug that could save the patient's life, even though many people suffer life-threatening bleeding ...

'Clot-busters' no more effective than traditional therapy in treating lung blood clots

May 16, 2011
Although so-called clot-busting drugs are commonly used in the treatment of some patients with blood clots in the lungs, a new study conducted by researchers in Spain and the U.S. indicates the agents do not appear to be ...

Clot-busting drug benefits intermediate-risk patients with pulmonary embolism

March 12, 2013
The clot-busting drug tenecteplase prevents death or circulatory collapse in a subgroup of patients with a blood clot in the lungs and appears to be especially useful in patients younger than 75, according to research presented ...

Clot-busters safe for treating moderate pulmonary embolism

March 27, 2012
Pulmonary embolism -- the sudden blockage of an artery in the lung -- is estimated to cause over 100,000 deaths each year in the U.S. Although thrombolytics, or "clot-buster" drugs, are currently reserved to treat only the ...

Unsuspected PE seldom linked to death in cancer patients

October 9, 2012
(HealthDay)—Unsuspected pulmonary embolism (UPE) is not associated with an increased risk of death in cancer patients when compared to patients without pulmonary embolism (PE), according to research published in the October ...

Recommended for you

How Gata4 helps mend a broken heart

August 15, 2017
During a heart attack, blood stops flowing into the heart; starved for oxygen, part of the heart muscle dies. The heart muscle does not regenerate; instead it replaces dead tissue with scars made of cells called fibroblasts ...

Injectable tissue patch could help repair damaged organs

August 14, 2017
A team of U of T Engineering researchers is mending broken hearts with an expanding tissue bandage a little smaller than a postage stamp.

'Fat but fit' are at increased risk of heart disease

August 14, 2017
Carrying extra weight could raise your risk of heart attack by more than a quarter, even if you are otherwise healthy.

Air pollution linked to cardiovascular disease; air purifiers may lessen impact

August 14, 2017
Exposure to high levels of air pollution increased stress hormone levels and negative metabolic changes in otherwise healthy, young adults in a recent study conducted in China. Air purifiers appeared to lessen the negative ...

Study hints at experimental therapy for heart fibrosis

August 14, 2017
Researchers report encouraging preclinical results as they pursue elusive therapeutic strategies to repair scarred and poorly functioning heart tissues after cardiac injury—describing an experimental molecular treatment ...

Scientists identify mutations in venous valve disease

August 14, 2017
A team of scientists has discovered that mutations in the genes FOXC2 and GJC2 are associated with defects in venous valves, flaps within veins that help maintain proper blood flow.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.